Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
All‐cause mortality (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status (expressed as new need for IMV, admission to ICU, or death by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in worsening of clinical status (expressed as new need for IMV,… compared with saline placebo (low certainty).
1 finding from 1 review
Induction of labour · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of labour · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Muscle strength · people with multifocal motor neuropathy
1 finding from 1 review
no estimate extracted
9 participants
Very low
Adverse events · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy
It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with SCIg (very low certainty).
1 finding from 1 review
RR 0.5 [0.18, 1.4]
9 participants
Very low
Proportion of participants with an improvement in disability scale used in the original study · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants with an improvement in disability scale… compared with placebo (low certainty).
1 finding from 1 review
RR 3 [0.89, 10.12]
18 participants
Low
Proportion of participants with an improvement of muscle strength · people with multifocal motor neuropathy
IVIg may leads to higher proportion of participants with an improvement of muscle strength compared with placebo (low certainty).
1 finding from 1 review
RR 11 [2.86, 42.25]
27 participants
Low
Proportion of participants with an improvement in disability at 12 months or later · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants in which at least 1 conduction block resolved after therapy · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants in which at least 1 conduction block… compared with placebo (low certainty).
1 finding from 1 review
RR 7 [0.95, 51.7]
28 participants
Low
Maintenance · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal · people with multifocal motor neuropathy
IVIg probably leads to higher proportion of IVIg‐treated participants with an increase in… compared with placebo (moderate certainty).
1 finding from 1 review
RR 2.43 [1.13, 5.24]
42 participants
Moderate
Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal · people with multifocal motor neuropathy
IVIg probably leads to lower proportion of IVIg‐treated participants with a decrease in muscle… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.2 [0.07, 0.54]
42 participants
Moderate
Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy
It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with placebo (very low certainty).
1 finding from 1 review
RR 10.33 [2.15, 49.77]
21 participants
Very low
Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks · people with asthma
Anti‐IL13 or anti‐IL4 agents probably leads to lower exacerbation requiring hospitalisation or ED visit compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in blood eosinophils (cells x 10*9/L) · children and adults with asthma
1 finding from 1 review